FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDexCom, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DXCM
DexCom, Inc. Stock AnalysisComprehensive stock analysis for DexCom, Inc. (DXCM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDXCM
DXCM
DexCom, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DXCM
  1. Home
  2. Stocks
  3. DexCom, Inc.

DexCom, Inc.

🇺🇸DXCM•NASDAQ

DexCom, Inc.

🇺🇸DXCM•NASDAQ
Market cap
$30.44B
Sentiment

Your view on DXCM

Mkt Cap
$30.44B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About DexCom, Inc.

Industry
Medical - Devices
Sector
Healthcare
CEO
Jacob Steven Leach
Headquarters
6340 Sequence Drive, San Diego, CA, US
Industry
Medical - Devices
Sector
Healthcare
CEO
Jacob Steven Leach
Headquarters
6340 Sequence Drive, San Diego, CA, US
Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.

Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for DexCom, Inc. from FRC's valuation model, read against the market price. DXCM last traded at $81.61, 31.6× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for DexCom, Inc.. Starting points for DexCom, Inc.: P/E 31.6, EPS $2.64, beta 1.44 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for DexCom, Inc.. DexCom, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for DexCom, Inc.. Trailing twelve-month EPS for DexCom, Inc. stands at $2.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$94.75

average of 16 firms, last 12 months

 

$94.75

Low $75.00

Median $95.50

High $115.00

 

Analyst Ratings

Buy20 firms, last 12 months
  • Strong Buy0
  • Buy19
  • Hold1
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.72$0.63$2.70$3.14
Low estimate$0.68$0.58$2.47$2.82
High estimate$0.77$0.67$2.77$3.28
No. of analysts15111516
Year-ago EPS$0.68$0.56$2.09—
Growth+5.2%+13.1%+29.3%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.38B$1.31B$5.23B$5.77B
Low estimate$1.37B$1.30B$5.21B$5.68B
High estimate$1.39B$1.32B$5.25B$5.87B
No. of analysts16112121
Year-ago revenue$1.26B$1.19B$4.66B—
Growth+9.9%+10.1%+12.2%—
Recent analyst actions15 rating and price-target changes, latest Oct 30, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for DexCom, Inc.. DexCom, Inc. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DXCM18 companies · 8 funds
Compare DXCM with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • BBNXBeta Bionics, Inc.Medical - Devices$684M
  • DRIODarioHealth Corp.Medical - Specialties$11M
  • GCTKGlucoTrack, Inc.Medical - Devices$179,582
  • MMEDMiniMed Group, Inc. Common StockMedical - Equipment & Services$5.2B
  • PODDInsulet CorporationMedical - Devices$10.1B
  • SENSSenseonics Holdings, Inc.Medical - Devices$597M

More Medical - Devices companies

  • LPTILongport, Inc.OTC$2,308
  • LUCDLucid Diagnostics Inc.NASDAQ$77M
  • LUDGLudwig Enterprises, Inc.OTC$4M
  • LUNGPulmonx CorporationNASDAQ$122M
  • MBOTMicrobot Medical Inc.NASDAQ$43M
  • MCRPFMicroPort Scientific CorporationOTC$2.9B
  • MDRSFMedartis Holding AGOTC$1.2B
  • MDTMedtronic plcNYSE$131.6B
  • MDXHFMedX Health CorpOTC$7M
  • MHTXManhattan Scientifics, Inc.OTC$55,928
  • MICRMicron Solutions, Inc.OTC$634
  • MMTCMicro Imaging Technology, Inc.OTC$901

ETFs holding DexCom, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.05%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.04%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets0.15%
  • VOVanguard Mid-Cap ETF$103.4B in assets0.30%
  • SNSRGlobal X - Internet of Things ETF$193M in assets5.93%
  • IHIiShares US Medical Devices ETF$4.0B in assets3.92%
  • MIGOMIG Core ETF$695M in assets3.10%
  • TMFGMotley Fool Global Opportunities ETF$333M in assets2.74%

Largest holders first, then the funds most concentrated in DXCM.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold DexCom, Inc., and how their positions are changing. At a $30.44B market value, institutional positions materially move DexCom, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by DexCom, Inc. executives and directors. Shares of DexCom, Inc. have traded between $54.11 and $93.25 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming DexCom, Inc.. DexCom, Inc. is a $30.44B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming DexCom, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for DexCom, Inc.. Coverage tracks DexCom, Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of DexCom, Inc.

DXCM Analysis
Good
Past2
Growth5
Health3
Profit5
Value1

News

Latest Market News